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RESEARCH NOTE
Validation of extracellular ligand–receptor 
interactions by Flow‑TriCEPS
Laura A. Lopez‑Garcia1, Levent Demiray1, Sandra Ruch‑Marder1, Ann‑Katrin Hopp2,3, Michael O. Hottiger2, 
Paul M. Helbling1 and Maria P. Pavlou1*
Abstract 
Objective: The advent of ligand‑based receptor capture methodologies, allows the identification of unknown recep‑
tor candidates for orphan extracellular ligands. However, further target validation can be tedious, laborious and time‑
consuming. Here, we present a methodology that provides a fast and cost‑efficient alternative for candidate target 
verification on living cells.
Results: In the described methodology a ligand of interest (e.g. transferrin, epidermal growth factor or insulin) was 
conjugated to a linker (TriCEPS) that carries a biotin. To confirm ligand/receptor interactions, the ligand–TriCEPS 
conjugates were first added onto living cells and cells were subsequently labeled with a streptavidin‑fluorophore and 
analyzed by flow cytometry (thus referred as Flow‑TriCEPS). Flow‑TriCEPS was also used to validate identified receptor 
candidates when combined with a siRNA knock down approach (i.e. reduction of expression levels). This approach 
is versatile as it can be applied for different classes of ligands (proteins, peptides, antibodies) and different cell lines. 
Moreover, the method is time‑efficient since it takes advantage of the large variety of commercially available (and 
certified) siRNAs.
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Introduction
Identifying the protein binding receptors of key ligands 
provides valuable mechanistic information regarding 
signal transduction, drug action or off-target effects. 
Recognizing the unmet need to decipher transient extra-
cellular interactions, the ligand-based receptor capture 
(LRC) technology was developed [1, 2]. The advantages 
of the LRC-TriCEPS™ (and its latest development LRC-
HATRIC [3]) methodology include versatility, no need 
for genetic manipulation, target identification on living 
cells and the ability to capture both stable and transient 
interactions.
The LRC methodologies have been applied to study 
numerous ligands ranging from small molecules to intact 
viruses and have revealed known and novel interactors 
[1, 3–8]. As with every discovery-based methodology, the 
resulting candidate targets should be further validated 
and confirmed, which can be a tedious, laborious and 
time-consuming exercise.
In the present technical note, we present a method for 
the fast validation and confirmation of receptor candi-
dates, which was demonstrated using different ligands 
and their well-established targets.
Main text
Methods
TriCEPS‑ligand coupling
20  μg of transferrin (TRFE), epidermal growth factor 
receptor (EGFR) antibody, insulin (INS) and glycine (Gly) 
were coupled to 10 μg of TriCEPS v.2.0 (biotin moiety) or 
TriCEPS-TAMRA (fluorophore moiety) in a total volume 
of 50 μl 25 mM HEPES pH 8.2 (90 min at 22 °C). Upon 
coupling, non-reacted N-hydroxysuccinimide (NHS) was 
quenched with 20 μg Gly.
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Cell incubation with TriCEPS‑coupled ligand
MDA-MB-231 and HEK293 cells were collected using 
5  mM ethylene-diamine-tetra-acetic acid, washed once 
with phosphate-buffered saline (PBS) pH 6.5 and incu-
bated with 1.2 μg of the corresponding TriCEPS-ligands 
(500,000 cells in 200 μl PBS pH 6.5 for 60 min at 4  °C). 
For competition experiments, cells were incubated with 
different amounts of unlabeled ligand TRFE or bovine 
serum albumin (BSA) (20  min at 22  °C) in PBS pH 7.4 
prior to addition of the TriCEPS-coupled ligand.
Flow cytometry
Upon incubation of cells with TriCEPS–coupled ligands, 
cells were washed twice with 400 μl of ice cold PBS buffer 
pH 6.5, labelled with streptavidin-R-phycoerythrin (PE) 
(Jackson) (30 min at 4 °C in the dark), washed twice and 
analyzed by flow cytometry.
siRNA knock down of receptor candidates
Ten nanomolar of scramble siRNA (AllStars Negative 
Control, Qiagen) and siRNA against human transfer-
rin receptor (TFR1) (Hs_TFRC_7, Hs_TFRC_5 and 
Hs_TFRC_11, Qiagen), human EGFR (Hs_EGFR_10, 
Qiagen), human insulin receptor (INSR) (Hs_INSR_3 
and Hs_INSR_4, Qiagen) and human insulin-like growth 
factor receptor (IGF1R) (Hs_IGF1R_8 and Hs_IGF1R_6, 
Qiagen) were used for reverse transfection of MDA-
MB-231 and HEK293 cells on a 6 well plate format using 
Lipofectamine RNAiMax (Invitrogen). The knock down 
efficiency of TFR1 on mRNA level in MDA-MB-231 cells 
was monitored by qRT-PCR. Knock down efficiency was 
tested by flow cytometric analysis using PE anti human 
CD71 (TFR1) (BioLegend), PE anti human EGFR (BioLe-
gend), PE anti human CD220 (INSR) (BD Bioscience) and 
PE anti human CD221 (IGF1R) (BD Bioscience) antibod-
ies using recommended conditions.
Microscopy using TriCEPS‑TAMRA
HEK293 cells were plated on cover slips previously 
coated with Poly l-Lys (0.01%) (EMD Millipore) on 12 
well plates and the ligand–TriCEPS–TAMRA conju-
gates (8 μg) were added in 500 μl RPMI media contain-
ing 1% fetal bovine serum (45 min at 4  °C, in the dark). 
Upon incubation, cells were fixed with 4% paraform-
aldehyde (15  min at 22  °C in the dark), and the cover 
slips were transferred to a microscope slide containing 
30 μl 4,6-diamidino-2-phenylindole (DAPI) (Invitrogen). 
Imaging was performed using the Leica SP8 inverse con-
focal microscope with support of the Center for Micros-
copy and Image Analysis, University of Zurich.
Results
Development of Flow‑TriCEPS as a method to determine 
ligand binding on living cells
In the first step of a LRC experiment, the tri-functional 
molecule (TriCEPS or HATRIC) is conjugated to the 
primary amines of the ligand of interest via a NHS-ester 
(Additional file  1: Figure S1). During the incubation of 
tri-functional molecule–ligand conjugates with mildly 
oxidized cells the second moiety (hydrazone) reacts with 
aldehydes of cell surface glycoproteins and decorates the 
cell surface. Finally, the third moiety (i.e. biotin) is used 
in order to pull down and thus enrich the tagged pro-
teins [1, 3]. When conjugates are added on non-oxidized 
cells, the hydrazone should not react (no aldehydes) 
and conjugates should bind only to the target of interest 
(if expressed). To confirm the binding of a ligand to its 
receptor, the third moiety (i.e. biotin) can be replaced or 
interact with a fluorophore and the binding visualized by 
microscopy or flow cytometry.
To explore this possibility, we used TRFE as ligand, 
because its target TFR1 (also known as CD71) is 
expressed in the vast majority of cell types including the 
breast cancer cell line (MDA-MB-231) [9]. TRFE coupled 
to TriCEPS (TRFE-TriCEPS) was added on oxidized and 
non-oxidized MDA-MB-231 cells. The TriCEPS mol-
ecule quenched with glycine to hydrolyze the NHS group 
was used as a negative control. Samples were labeled 
with streptavidin-PE (Str-PE) that reacts with biotin of 
TriCEPS and analyzed by flow cytometry. In parallel, 
the same number of cells was incubated with Str-PE to 
assess the background signal. As shown by the shift of 
median fluorescence values, both conjugates bound to 
the surface of oxidized cells to a comparable extent likely 
due to the covalent labeling of glycoproteins (Additional 
file 1: Figure S1, left panel). Non-oxidized cells incubated 
with quenched TriCEPS (Gly-TriCEPS) showed a strong 
reduction of the median fluorescence values compared 
to cells incubated with TRFE-TriCEPS (Additional file 1: 
Figure S1, right panel). Given that quenched TriCEPS 
should not react with non-oxidized cells, the observed 
shift in the median fluorescence intensity in the cells 
treated with TRFE-TriCEPS was very likely due to the 
binding of TRFE to its corresponding target on the sur-
face of the cells.
To assess if the observed signal in the above-described 
TRFE-TriCEPS experiment originated from the spe-
cific interaction of TRFE with its target, a competition 
experiment was performed. Non-oxidized cells were pre-
treated with increasing amounts of unlabeled TRFE or 
BSA (1, 10 and 50 times excess) before they were incu-
bated with the TRFE–TriCEPS conjugate. In parallel, 
one sample was treated with quenched TriCEPS (Gly-
TriCEPS). All samples were subsequently labeled with 
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Fig. 1 Development of Flow‑TriCEPS as a method to determine ligand binding on living cells. a Flow cytometric analysis to determine binding 
of transferrin coupled to TriCEPS (TRFE‑TriCEPS) to the surface of living MDA‑MB‑231 cells (red line). Competition assay by adding increasing 
amount of unlabeled TRFE. A representative experiment out of two is shown. b Addition of BSA, cannot compete the TRFE‑TriCEPS‑PE signal on 
MDA‑MD‑231 cells (red line). c Flow cytometric analysis to determine binding of antiCD71‑PE labelled on MDA‑MB‑231 cells transfected with 
siRNA TFR1 (Hs_TFR1_5) at different time points, Igg‑PE was used as control. d Flow cytometric analysis to determine binding of TRFE‑TriCEPS on 
MDA‑MB‑231 cells transfected with siRNA TFR1 (Hs_TFR1_5) at different time points, cells labelled with PE‑Streptavidin were used as control. Similar 
results were obtained by using Hs_TFR1_11 and Hs_TFR1_7 siRNA for 72 h. A representative experiment out of 3 is shown. e Confocal microscopy 
using TriCEPS‑TAMRA to detect binding of TRFE‑TriCEPS‑TAMRA on the surface of living HEK293 cells. As control of the specificity TRFE‑TriCEPS was 
out‑competed with excess of unlabeled TRFE
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Str-PE. As above, cells of one sample were incubated only 
with Str-PE to assess the background signal. As shown 
by the shift of median fluorescence values, the intensity 
decreased for the samples that were pretreated with unla-
beled TRFE in a dose–response manner, compared to the 
non-pretreated cells (Fig. 1a). Pre-treatment of cells with 
increasing amounts of BSA did not result in a decrease in 
the signal intensity (Fig. 1b), indicating that the binding 
of the TRFE–TriCEPS conjugate was out-competed by 
the excess of unlabeled TRFE and that the observed com-
petition was not due to interference caused by the high 
protein concentration in the sample, but rather specific.
To further validate that the signal was due to a specific 
interaction of TRFE with its receptor, the expression of 
TFR1 was downregulated in MDA-MB-231 cells (Addi-
tional file 2: Figure S2a). Cells were transfected with anti-
TFR1 siRNA for 24, 48 or 72 h and the expression levels 
of TFR1 on the cell surface were quantified by incubat-
ing cells with an anti-CD71-PE antibody followed by 
flow cytometric analysis. Cells transfected with scram-
ble siRNA served as negative control (Additional file  2: 
Figure S2b, left panel). Based on the observed shift of 
median fluorescence with the transfected cells (Fig.  1c, 
Additional file 2: Figure S2b), the TFR1 levels were over 
time gradually reduced, indicating that the used siRNA 
was indeed specific for TFR1. When the transfected 
cells were subsequently incubated with the TRFE–Tri-
CEPS conjugate and labeled with Str-PE, the acquired 
fluorescence signal closely mimicked the signal intensity 
staining of the anti-CD71 antibody, suggesting that the 
observed signal was due to the interaction of TRFE with 
TFR1 (Fig. 1d).
To ensure that the ligand–TriCEPS conjugate did 
not enter the cells, cells treated in the same manner as 
described above were analyzed by microscopy (Fig.  1e). 
The TRFE–TriCEPS–TAMRA conjugate was only 
located on the surface of cells. Together, these experi-
ments provide strong evidence that coupling of TriCEPS 
to TRFE followed by flow cytometry is suitable to moni-
tor the binding of ligands on the surface of living cells.
Verification of ligand binding to LRC‑HATRIC identified 
targets by siRNA knockdown of putative candidates 
and subsequently analysis with Flow‑TriCEPS
We next investigated if the developed Flow-TriCEPS 
pipeline was also applicable to different classes of ligands. 
Two ligands were selected (i) an antibody against EGFR 
(anti-EGFR) and (ii) a peptide (insulin) that is known 
to bind to the INSR and IGF1R [10]. The targets of the 
above-mentioned ligands were confirmed by independ-
ent LRC-HATRIC experiments (Additional file 3: Figure 
S3).
Anti‑EGFR antibody To verify that the anti-EGFR anti-
body would only bind to EGFR, we reduced the expression 
of EGFR by siRNA knockdown and assessed binding of 
the ligand in this perturbed conditions by Flow-TriCEPS. 
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Fig. 2 Flow‑TriCEPS knock down target validation of a protein (TRFE) and an antibody (anti EGFR) on MDA‑MB‑231 cells. a Flow cytometric analysis 
comparing binding of anti EGFR‑PE labelled antibody on MDA‑MB‑231 cells transfected with scrambled or EGFR siRNA (Hs_EGFR_10) for 72 h. 
Igg‑PE was used as control. A representative experiment out of two is shown. b Flow cytometric analysis comparing binding of EGFR Ab‑TriCEPS on 
MDA‑MB‑231 cells transfected with scrambled or EGFR siRNA (Hs_EGFR_10) for 72 h. Gly‑TriCEPS and cells labelled with PE‑streptavidin were used 
as control. A representative experiment out of two is shown
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Fig. 3 Flow‑TriCEPS knock down target validation of a peptide hormone (insulin) on HEK293 cells. a Flow cytometric analysis to determine binding 
of anti INSR Ab‑PE (left panel) and anti IGF1R Ab‑PE (right panel) on HEK293 cells transfected with siRNA to knock down INSR (Hs_INSR_3), IGF1R 
(Hs_IGF1R_8) or both receptors simultaneously for 72 h. Cells transfected with scrambled siRNA were used as control. A representative experiment 
out of 3 is shown. Similar results were obtained by using Hs_INSR_4 and Hs_IGF1R_6 siRNA. b Flow cytometric analysis to determine binding of 
INS‑TriCEPS on HEK293 cells transfected with siRNA to knock down INSR (Hs_INSR_3) for 72 h (top left panel), siRNA to knock down IGF1R (Hs_
IGF1R_8) for 72 h (top right panel) and siRNA to simultaneously knock down INSR and IGF1R for 72 h (low panel). Cells transfected with scrambled 
siRNA were used as control. A representative experiment out of 3 is shown. Similar results were obtained by using Hs_INSR_4 and Hs_IGF1R_6 
siRNA
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MDA-MB-231 cells were transfected for 72 h with anti-
EGFR siRNA and scramble siRNA, respectively. Reduc-
tion of EGFR protein levels was assessed by incubating 
cells with an anti-EGFR-PE antibody followed by flow 
cytometric analysis. Based on the shift of median fluo-
rescence, the expression level of EGFR on the cell surface 
was drastically reduced in the cells transfected with anti-
EGFR siRNA compared to cell transfected with scrambled 
siRNA, confirming the knockdown of EGFR on protein 
level (Fig.  2a). When those transfected cells were incu-
bated with an anti-EGFR-antibody–TriCEPS conjugate 
and further labeled with Str-PE, the acquired fluorescence 
signal was comparably reduced, indicating that cells with 
lower EGFR expression levels bound the anti-EGFR-anti-
body to lower extent (Fig. 2b).
Insulin To provide further evidence for the binding of 
INS to INSR and IGF1R, the expression levels of either 
INSR or IGF1R alone or in combination in HEK293 cells 
were perturbed. Therefore, cells were transfected with a 
siRNA against INSR and IGF1R individually or in com-
bination. The same transfection of cells with scrambled 
siRNA served as negative control. The success of trans-
fection was assessed by incubating transfected cells with 
PE-labeled anti-human CD220 (against INSR) and anti-
human CD221 (against IGF1R) antibodies followed by 
flow cytometric analysis. Based on the shift of median 
fluorescence across cells transfected with the different 
siRNA combinations, the protein expression level of INSR 
was not affected in cells transfected with either scramble 
siRNA or anti-IGF1R siRNA. However, INSR protein lev-
els were drastically reduced in cells transfected with only 
siRNA against INSR or double transfected cells (i.e. INSR 
and IGF1R) (Fig. 3a, left panel). In a similar manner, the 
protein level of IGF1R was not affected in cells transfected 
with scramble siRNA but was drastically reduced in cells 
transfected with a siRNA against IGF1R or doubly trans-
fected cells (i.e. INSR and IGF1R) (Fig.  3a, right panel). 
Notably, protein levels of IGF1R showed a small increase 
in cells lacking INSR, an observation reported already 
before in the literature [10].
Finally, we investigated the binding of INS in trans-
fected cells using Flow-TriCEPS. When compared to cells 
transfected with scrambled siRNA, the generated signal 
by INS-TriCEPS was not reduced in cells expressing nei-
ther INSR nor IGF1R (Fig.  3b, left and right top panels 
respectively). This could be due to functional compen-
sation between INSR and IGF1R [10]. However, fluores-
cence signal is drastically reduced in cells lacking both, 
INSR and IGF1R (Fig.  3b, low panel), suggesting that 
combinatorial knock-down of multiple targets may be 
necessary to demonstrate reduced ligand binding.
Discussion
Validating previously identified ligand–receptor interac-
tions can for different reasons be challenging and time 
consuming. Here, we provide evidence in three different 
conditions that the developed Flow-TriCEPS methodol-
ogy can monitor binding of extracellular ligands to their 
receptors on living cells. Additionally, we showed that 
candidate targets identified by the LRC methodologies 
can be quickly validated by combining Flow-TriCEPS 
with a siRNA mediated knock down approach for a par-
ticular receptor protein. This approach is versatile as it 
can be applied for different classes of ligands (proteins, 
peptides, antibodies) and different cell lines. The method 
is also time- and cost-efficient and takes advantage of 
the large variety of commercially available (and certified) 
siRNAs. Additionally, should a ligand bind to several 
interaction candidates, the combinatorial knock down of 
these targets can be easily performed as demonstrated in 
the case of INS.
Limitations
• Not all cell types can be readily transfected, which 
might require additional optimization.
• In case that a ligand has more than one candidate tar-
gets, the combinatorial knock down of these should 
be performed, as single knock downs may lead to 
increase of the other targets compensating ligand 
binding.
Additional files
Additional file 1: Figure S1. a Representation of HATRIC, TriCEPS v.2.0 
and TriCEPS–TAMRA molecules. b TriCEPS–ligand conjugates bind to the 
cell surface on mildly oxidized MDA‑MB‑231 cells to the same extend (left 
panel). TriCEPS coupled ligand binds only to the target receptor on non‑
oxidized cells (right panel). A representative experiment out of 3 is shown.
Additional file 2: Figure S2. a qRT‑PCR confirming knock down of TFR1 
(Hs_TFR1_5) at RNA level on MDA‑MB‑231 cells at different time points. b 
Igg‑PE was used as control at different TFR1 knock down time points. Igg‑
PE signal is overlapping and displaying no fluorescent shift (right panel).
Additional file 3: Figure S3. LRC‑ HATRIC experiment comparing TRFE‑
HATRIC and EGFR Ab‑HATRIC samples on MDA‑MB‑231 cells (left panel) 
and INS‑HATRIC and TRFE‑HATRIC samples on HEK293 cells (right panel). 
Data is shown at the protein level and proteins were annotated using the 
Uniprot database. Y axis = − Log10 (adj. p value), X‑axis = log2 fold change 
compared to the other sample.
Abbreviations
LRC: ligand‑based receptor capture; TRFE: transferrin; EGFR: epidermal 
growth factor receptor; INS: insulin; Gly: glycine; NHS: N‑hydroxysuccinimide; 
BSA: bovine serum albumin; PE: R‑Phycoerythrin; TFR1: transferrin receptor; 
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INSR: insulin receptor; IGFR1: insulin‑like growth factor receptor; Str‑PE: 
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